A practical reference on GIP receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-12-18. Anything still debated is marked as such rather than presented as settled.
Characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity and related-substance profiling, with ultraviolet detection near 214 nanometers. Mass spectrometry confirms molecular mass and reveals modifications such as oxidation or deamidation. Peptide mapping after enzymatic digestion verifies the amino acid sequence, while amino acid analysis supplies compositional data. Circular dichroism and infrared spectroscopy are used to assess secondary structure, particularly the alpha-helical content that influences aggregation behavior in solution.
Common degradation routes include hydrolysis of labile amide bonds, deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation. Aggregates can form during freeze-thaw cycling, at elevated pH, or when peptide concentration is high. Each route produces characteristic chromatographic or mass shifts that are tracked during stability studies. Whether a given minor impurity alters biological activity is often an open question, and specification limits are typically set on identity and purity rather than on functional data for trace species.
Lyophilized material is generally held at -20 degrees Celsius or lower, desiccated and protected from light, where it remains stable for extended periods. Reconstituted or ready-to-use solution is usually kept at 2 to 8 degrees Celsius with minimal agitation. Repeated freeze-thaw cycles should be avoided because they promote aggregation and reduce the soluble monomer fraction. Shipment of frozen solid commonly uses dry ice, while refrigerated liquid moves with validated cold packs. Stability beyond documented periods is not established.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid form |
| Purity assay | 95 percent or greater by RP-HPLC | Typical research-grade specification |
| Storage temperature | 2 to 8 degrees Celsius | Formulated solution, do not freeze |
| Common analytical method | LC-MS with peptide mapping | Identity and impurity confirmation |
| Primary degradation routes | Deamidation, oxidation, aggregation | Tracked in stability programs |
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
== Dosing == Since alpha-glucosidase inhibitors are competitive inhibitors of digestive enzymes, they must be taken at the start of main meals to have maximal effect. Their effects on blood sugar levels following meals will depend on the amount of complex carbohydrates in the meal.
Adding to the speculation, it was revealed that Trump had made an hours-long visit to Walter Reed National Military Medical Center, his third visit within a year, where doctors administered what Trump says was his fourth Montreal Cognitive Assessment test. White House spokesperson Davis Ingle refuted concerns about Trump's health, stating the president had completed multiple engagements with open press slots for the end of the week, and labeled the concerns as "left-wing conspiracies". When questioned about his opinion of the president receiving four medical checkups since the beginning of his second term, Mehmet Oz told reporters that Trump was in perfect health and kept returning for checkups as he likes the results and aces the tests every visit. On June 3, during a House Foreign Affairs Committee Representative Ted Lieu (D-CA) questioned Secretary of State Marco Rubio over Trump's apparent sleeping in multiple public appearances such as Cabinet meetings. Rubio refuted the idea that Trump was sleeping, claiming that instead Trump does not sleep, and when presented with a video of Trump, appearing to sleep next to Rubio speaking about the Iran war Rubio doubled down claiming that Trump was not sleeping. Lieu expressed concern about how foreign leaders perceive Trump and the United States, and presented a foreign news segment video in which they mocked Trump "fighting sleep" during a Memorial Day ceremony. Trump also appeared to fall asleep at Game 3 of the 2026 NBA finals at Madison Square Garden.
== Early life == Gerald Ernst (Jerry) Gallwas was born in Whittier, California, the only child of Ernst and Lois Gallwas. Gallwas' father held many jobs, including farmer, iron worker, and commercial fisherman. His mother was a schoolteacher. Both parents were outdoor enthusiasts. Gallwas, a native of California, first showed an interest in climbing in junior high school. Using a Sierra Club publication drawing as a guide, he practiced rappelling on a hemp rope. In 1950, Gallwas and his family vacationed in Yosemite National Park. On the front of Best Studio, now the Ansel Adams Gallery, Gallwas spied a picture of John Salathé standing on the tip of the Lost Arrow taking a photograph of his climbing partner, Anton Nelson, as Nelson was rappelling. Gallwas imagined one day taking a photo where Salathé stood. In 1954, Gallwas fulfilled that dream by completing the 5th ascent of the spire with Wayne Merry.
==== Never marketed ==== 4′-Fluorococaine (also a Dopamine reuptake inhibitor) Delucemine (also an NMDA antagonist) Mesembrenone (also a weak PDE4 inhibitor (found in Sceletium tortuosum (kanna)) Mesembrine (also a weak PDE4 inhibitor (found in Sceletium tortuosum (kanna)) Roxindole (EMD-49,980) (also a 5-HT1A and D2-like receptor agonist)
Sources: en.wikipedia.org
Sanctioned Parts List – a habitation / factory ship So Much For Subtlety – a habitation / factory ship All Through With This Niceness And Negotiation Stuff – a warship Attitude Adjuster – a warship Of Course I Still Love You – an ambassador ship Funny, It Worked Last Time... – an ambassador ship
Improper management of health care waste can have both direct and indirect health consequences for health personnel, community members and on the environment. Indirect consequences in the form of toxic emissions from inadequate burning of medical waste, or the production of millions of used syringes in a period of three to four weeks from an insufficiently well planned mass immunization campaign. Biomedical waste is not limited to medical instruments; it includes medicine, waste stored in red biohazard bags, and materials used for patient care, such as cotton and bandaids. The most serious effect that biomedical waste has on our seas is the discharge of poisons into the waters that could then be consumed by ocean life creatures. Toxins would interject into the food chain and eventually reach humans who consume sea creatures. Human exposure to such toxins can stunt human growth development and cause birth defects. The high volume of plastic use in the medical field also poses a dangerous threat to the environment. According to North and Halden, 85% of disposable plastic materials make up all medical equipment. Our current reliance on plastic materials is rooted in their unique capabilities to be lightweight, cost-effective, and durable while preserving the sterility of medical equipment. In addition to the serious health implications of releasing harmful toxins in the environment from medical waste deposits, introducing this volume of single-use plastics can catalyze the compounding health detriments caused by macro and microplastics.
AZD-7268 is a δ-opioid receptor agonist which was under development for the treatment of major depressive disorder but was never marketed. It is taken by mouth. The affinity (Ki) of AZD-7268 for the δ-opioid receptor was reported to be 2.7 nM and its selectivity for this receptor over the μ-opioid receptor was reported to be 2,000-fold. No animal studies of AZD-7268 appear to have been published. In addition to putative antidepressant effects, AZD-7268 might have anxiolytic effects. Structurally, AZD-7268 was derived from SNC-80. Dose-limiting side effects of AZD-7268 in clinical trials included syncope (fainting), hypotension (low blood pressure), and dizziness. AZD-7268 was first described by 2007. Its development was discontinued in 2010. It reached phase 2 clinical trials prior to the discontinuation of its development. No reason was given for the discontinuation of its development. However, the drug was found to be ineffective for major depressive disorder in a phase 2 clinical trial of 231 participants comparing it with placebo and escitalopram. The drug was under development by AstraZeneca.
Sources: en.wikipedia.org
The triangular teeth can reach 7.5 cm (3.0 in). In juveniles, they are elongated and pointy but become broader and more serrated as they develop into adults. This reflects a shift from a diet mainly of fish to the incorporation of marine mammals. The front teeth are adapted for penetrating prey while the rear teeth, flattened at the sides and bent backwards, are designed for tearing. A total of around 300 teeth are arranged in rows like a conveyor belt, with teeth at the back moving to replace those at the front. The jaws are separate from the skull and are connected to the body entirely by muscles and tendons, allowing them to extend forward. A 2008 study using a computer scan of a 2.5 m (8.2 ft) long and 240 kg (530 lb) juvenile white shark determined that the specimen could exert a bite force of 1,602 newtons (360 lbf) in the front and 3,131 newtons (704 lbf) in the back. From this, the researchers calculated that a specimen 6.4 m (21 ft) long and weighing 3,324 kg (7,328 lb) could exert a bite force of 9,320 newtons (2,100 lbf) in the front and 18,216 newtons (4,095 lbf) in the back. The jaws are strengthened by mineralized cartilage; this is lacking in young white sharks, which have to eat softer food.
In 2024, Lawrence Berkeley National Laboratory published a reliable way to make element 116, livermorium, using a titanium beam to irradiate a plutonium foil. This method may be useful in producing several more elements beyond Oganesson, element 118.
== Etymology == The first written use of the term "vegetarian" originated in the early 19th century, when authors referred to a vegetable regimen diet. Historically, 'vegetable' could be used to refer to any type of edible vegetation. Modern dictionaries explain its origin as a compound of vegetable (adjective) and the suffix -arian (in the sense of agrarian). The term was popularized with the foundation of the Vegetarian Society in Manchester in 1847, although it has been in use since around 1839 to refer to what was previously called a vegetable regimen or diet. It was used in writing first attributed to actress, writer and abolitionist Fanny Kemble, in her Journal of a Residence on a Georgian plantation in 1838–1839. The earliest occurrences of the term seem to be related to Alcott House—a school on the north side of Ham Common, London—which was opened in July 1838 by James Pierrepont Greaves. From 1841, it was known as A Concordium, or Industry Harmony College, and the institution then began to publish its own pamphlet, The Healthian. It provides some of the earliest appearances of the term "vegetarian".
In 1996, as part of Pizza Hut's global advertising strategy using celebrities, Formula One driver Damon Hill and BBC motorsport commentator Murray Walker advertised the stuffed crust pizza, which parodies Walker's extravagant style. Talk show host Jonathan Ross co-starred in an ad with American model Caprice Bourret. They advertised the new stuffed crust pizza, with Jonathan Ross saying "stuffed cwust" due to his rhotacism. Following England's defeat to Germany on penalties in the semifinals of Euro '96, Gareth Southgate, Stuart Pearce, and Chris Waddle featured in an advertisement, which shows Southgate wearing a paper bag over his head in shame as his penalty miss allowed England to lose the shootout. Waddle and Pearce, who both missed in a shootout vs West Germany at World Cup '90, are ridiculing him, emphasizing the word "miss" at every opportunity. After Southgate finishes his pizza, he takes off his paper bag, heads for the door, and bangs his head against the wall. Pearce responds with, "this time he's hit the post".
Sources: en.wikipedia.org
Reversed-phase high-performance liquid chromatography is the standard approach, separating the main peak from related impurities. Ultraviolet detection near 214 nanometers captures the peptide backbone. Mass spectrometry is then used alongside chromatography to confirm identity and detect covalent modifications.
Cycling between frozen and liquid states concentrates the peptide at ice interfaces, which favors non-covalent association. The resulting aggregates may be invisible to simple assays yet alter recovery and apparent potency. Limiting the number of cycles and aliquoting before storage are common mitigations.
Tryptophan and methionine side chains can undergo photo-induced oxidation, so amber glass or opaque packaging is typical. The effect is gradual and depends on wavelength and exposure time. Light protection is usually specified for both solid and solution forms.
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.